Elypta Granted US Patent for its Liquid Biopsy Method based on Cancer Metabolism
Stockholm, January 27, 2020: The molecular diagnostics firm Elypta announced today that it has been granted a patent by the United States Patent and Trademark Office for its novel liquid biopsy method for cancer diagnostics. The patent (US010895576) concerns a method for screening for renal cell carcinoma, the most common form of kidney cancer, by measuring specific metabolites – glycosaminoglycans (GAGs) – non-invasively, through for example blood or urine samples.Elypta was founded in 2017 following an initial discovery in the Nielsen lab, Chalmers University of Technology in Sweden, that